X4-tropic human immunodeficiency virus IIIB utilizes CXCR4 as coreceptor, as distinct from R5X4-tropic viruses

Microbiology and Immunology

Volumn 57, Issue 6, 2013, Pages 437-444

  Islam, Salequl ^a,b   Hoque, Sheikh Ariful ^a,c   Adnan, Nihad ^b,d   Tanaka, Atsushi ^e   Jinno Oue, Atsushi ^a   Hoshino, Hiroo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

^c UNIVERSITY OF DHAKA   (Bangladesh)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

C X C chemokine receptor type 4; Coreceptor; Deletion mutant; X4 R5X4 tropic HIV

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; RNA DIRECTED DNA POLYMERASE; VIRUS ANTIGEN; VIRUS DNA;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1IIIB; IMMUNOFLUORESCENCE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; R5 TROPIC HUMAN IMMUNODEFICIENCY VIRUS; R5X4 TROPIC HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE ANALYSIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS STRAIN; X4 TROPIC HUMAN IMMUNODEFICIENCY VIRUS;

FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HIV; HUMANS; POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; RECEPTORS, HIV; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION; VIRAL TROPISM; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879397025     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12051     Document Type: Article

References (28)

1. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-7.
2. Klatzmann D., Barre-Sinoussi F., Nugeyre M.T., Danquet C., Vilmer E., Griscelli C., Brun-Veziret F., Rouzioux C., Gluckman J.C., Chermann J.C., Montagnier L. (1984) Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 225: 59-63.
3. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
4. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-7.
5. Dimitrov D.S. (2004) Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2: 109-22.
6. Smith A.E., Helenius A. (2004) How viruses enter animal cells. Science 304: 237-42.
7. Shimizu N., Tanaka A., Oue A., Mori T., Ohtsuki T., Apichartpiyakul C., Uchiumi H., Nojima Y., Hoshino H. (2009) Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 23: 761-9.
8. Gharu L., Ringe R., Bhattacharya J. (2012) Evidence of extended alternate coreceptor usage by HIV-1 clade C envelope obtained from an Indian patient. Virus Res 163: 410-4.
9. Rucker J., Edinger A.L., Sharron M., Samson M., Lee B., Berson J.F., Yi Y., Margulies B., Collman R.G., Doranz B.J., Parmentier M., Doms R.W. (1997) Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 71: 8999-9007.
10. Rosenberg Y.J., Anderson A.O., Pabst R. (1998) HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? Immunol Today 19: 10-17.
11. Wilkin T.J., Su Z., Kuritzkes D.R., Hughes M., Flexner C., Gross R., Coakley E., Greaves W., Godfrey C., Skolnik P.R., Timpone J., Rodriguez B., Gulick R.M. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44: 591-5.
12. Samleerat T., Phiayura P., Hongjaisee S., Sirirungsi W., Ngo-Giang-Huong N., Barin F. (2012) High prevalence of CXCR4-using viruses in vertically HIV-1-infected infants in Thailand. J Int AIDS Soc 15: 18230.
13. Lockey T.D., Slobod K.S., Rencher S.D., Srinivas R.V., Hurwitz J.L. (1996) Fluctuating diversity in the HTLV-IIIB virus stock: implications for neutralization and challenge experiments. AIDS Res Hum Retroviruses 12: 1297-9.
14. Keogan S., Passic S., Krebs F.C. (2012) Infection by CXCR4-tropic human immunodeficiency virus type 1 is inhibited by the cationic cell-penetrating peptide derived from HIV-1 Tat. Int J Pept 2012: 349427.
15. Shimizu N., Tanaka A., Oue A., Mori T., Apichartpiyakul C., Hoshino H. (2008) A short amino acid sequence containing tyrosine in the N-terminal region of G protein-coupled receptors is critical for their potential use as co-receptors for human and simian immunodeficiency viruses. J Gen Virol 89: 3126-36.
16. Soda Y., Shimizu N., Jinno A., Liu H.Y., Kanbe K., Kitamura T., Hoshino H. (1999) Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 258: 313-21.
17. Kawakami Y., Rosenberg S.A. (1997) Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 14: 173-92.
18. Nishiyama C., Nishiyama M., Ito T., Masaki S., Maeda K., Masuoka N., Yamane H., Kitamura T., Ogawa H., Okumura K. (2004) Overproduction of PU.1 in mast cell progenitors: its effect on monocyte- and mast cell-specific gene expression. Biochem Biophys Res Commun 313: 516-21.
19. Nolan G.P., Shatzman A.R. (1998) Expression vectors and delivery systems. Curr Opin Biotechnol 9: 447-50.
20. Shimizu N.S., Shimizu N.G., Takeuchi Y., Hoshino H. (1994) Isolation and characterization of human immunodeficiency virus type 1 variants infectious to brain-derived cells: detection of common point mutations in the V3 region of the env gene of the variants. J Virol 68: 6130-5.
21. Ratner L., Fisher A., Jagodzinski L.L., Liou R.S., Mitsuya H., Gallo R.C., Wong-Staal F. (1987) Complete nucleotide sequences of functional clones of the virus associated with the acquired immunodeficiency syndrome, HTLV-III/LAV. Haematol Blood Transfus 31: 404-6.
22. Yamaguchi K., Byrn R.A. (1995) Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations. Biochim Biophys Acta 1253: 136-40.
23. Jinno A., Shimizu N., Soda Y., Haraguchi Y., Kitamura T., Hoshino H. (1998) Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection. Biochem Biophys Res Commun 243: 497-502.
24. Hoshino H., Esumi H., Miwa M., Shimoyama M., Minato K., Tobinai K., Hirose M., Watanabe S., Inada N., Kinoshita K., Kamihira S., Ichimaru M., Sugimura T. (1983) Establishment and characterization of 10 cell lines derived from patients with adult T-cell leukemia. Proc Natl Acad Sci USA 80: 6061-5.
25. Seibert C., Veldkamp C.T., Peterson F.C., Chait B.T., Volkman B.F., Sakmar T.P. (2008) Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases. Biochemistry 47(11): 251-62.
26. Chalmet K., Dauwe K., Foquet L., Baatz F., Seguin-Devaux C., Van Der Gucht B., Vogelaers D., Vandekerckhove L., Plum J., Verhofstede C. (2012) Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 205: 174-84.
27. Farzan M., Choe H., Vaca L., Martin K., Sun Y., Desjardins E., Ruffing N., Wu L., Wyatt R., Gerard N., Gerard C., Sodroski J. (1998) A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 72: 1160-4.
28. Hatse S., Princen K., Gerlach L.O., Bridger G., Henson G., De Clercq E., Schwartz T.W., Schols D. (2001) Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol 60: 164-73.